Enlivex announces interim 6-month efficacy data from Phase I of Allocetra trial

Enlivex Therapeutics (ENLV) announced positive interim six-month efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra trial in patients with moderate to severe knee osteoarthritis. Key highlights: Statistically significant 47.0% average reduction of reported pain compared to average pain level at baseline; 46% improvement in joint function and 40% improvement in joint stiffness; 83% of the patients were still considered as responders to treatment after 6 months; No serious adverse events; Efficacy continues to display strong persistence and durability over time, maintaining the 3-month positive effect